Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer (original) (raw)

Journal Article

,

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

,

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

,

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

,

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

,

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

,

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

,

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

,

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

Affiliations of authors : National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY); Department of Oncology, Mayo Clinic, Rochester, MN (JNI); Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM); Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)

Search for other works by this author on:

Revision received:

04 December 2007

Accepted:

10 January 2008

Published:

20 February 2008

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Judith-Anne W. Chapman, Daniel Meng, Lois Shepherd, Wendy Parulekar, James N. Ingle, Hyman B. Muss, Michael Palmer, Changhong Yu, Paul E. Goss, Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer, JNCI: Journal of the National Cancer Institute, Volume 100, Issue 4, 20 February 2008, Pages 252–260, https://doi.org/10.1093/jnci/djn014
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

Background

Older women with early-stage breast cancer experience higher rates of non–breast cancer-related death. We examined factors associated with cause-specific death in a large cohort of breast cancer patients treated with extended adjuvant endocrine therapy.

Methods

In the MA.17 trial, conducted by the National Cancer Institute of Canada Clinical Trials Group, 5170 breast cancer patients (median age = 62 years; range = 32–94 years) who were disease free after approximately 5 years of adjuvant tamoxifen treatment were randomly assigned to treatment with letrozole (2583 women) or placebo (2587 women). The median follow-up was 3.9 years (range0–7 years). We investigated the association of 11 baseline factors with the competing risks of death from breast cancer, other malignancies, and other causes. All statistical tests were two-sided likelihood ratio criterion tests.

Results

During follow-up, 256 deaths were reported (102 from breast cancer, 50 from other malignancies, 100 from other causes, and four from an unknown cause). Non–breast cancer deaths accounted for 60% of the 252 known deaths (72% for those ≥70 years and 48% for those <70 years). Two baseline factors were differentially associated with type of death: cardiovascular disease was associated with a statistically significant increased risk of death from other causes ( P .002), and osteoporosis was associated with a statistically significant increased risk of death from other malignancies ( P .05). An increased risk of breast cancer–specific death was associated with lymph node involvement ( P < .001). Increased risk of death from all three causes was associated with older age ( P < .001).

Conclusions

Non–breast cancer-related deaths were more common than breast cancer–specific deaths in this cohort of 5-year breast cancer survivors, especially among older women.

© The Author 2008. Published by Oxford University Press.

Topic:

• osteoporosis
• cardiovascular diseases
• cancer
• cause of death
• follow-up
• tamoxifen
• lymph nodes
• breast cancer
• letrozole
• older adult
• hormonal therapy, adjuvant

You do not currently have access to this article.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer - 24 Hours access

EUR €38.00

GBP £33.00

USD $41.00

Rental

This article is also available for rental through DeepDyve.

Citations

Views

Altmetric

Metrics

Total Views 1,510

1,024 Pageviews

486 PDF Downloads

Since 12/1/2016

Citations

133 Web of Science

×

Email alerts

Citing articles via

• Latest

• Most Read

• Most Cited

More from Oxford Academic